Targeting p38α in cancer: challenges, opportunities, and emerging strategies
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley +1 more source
Pharmacovigilance analysis of iodinated contrast media related respiratory adverse effects based on the FDA adverse event reporting system. [PDF]
Rui Y +7 more
europepmc +1 more source
Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta +10 more
wiley +1 more source
Exploring adverse events associated with vosoritide monotherapy: Insights from the FDA Adverse Event Reporting System. [PDF]
Li X, Luo X, Liu F, Wang C, Li X, Yu H.
europepmc +1 more source
Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley +1 more source
Don Sutherland, Maura Ricketts, Ping Yan
doaj +1 more source
Research Domain Criteria and Deaths by Suicide in the National Violent Death Reporting System.
Cochran SD +4 more
europepmc +1 more source
Adverse events associated with cyclophosphamide: A pharmacovigilance study using the FDA adverse event reporting system. [PDF]
Zhang H, Lin M, Zhao D, Fu Y.
europepmc +1 more source

